Dutasteride: Why don't some doctors prescribe it if it's stronger than finasteride?

Dutasteride is approved for benign prostatic hyperplasia (BPH). It is also approved for male hair loss in South Korea and Japan, and is prescribed off-label for hair loss in the US, the EU and the UK. It works by inhibiting 5-alpha reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT), a hormone involved in male pattern hair loss. Even though dutasteride is more potent than finasteride in its ability to reduce DHT levels, not all doctors prescribe it. There are several reasons for this cautious approach.

Side Effects:

One reason some doctors hesitate is side effects. Dutasteride blocks both forms of 5-alpha reductase and lowers DHT more than finasteride, and some doctors are cautious about what stronger DHT suppression means. In a 2019 meta-analysis of three 24-week trials (576 men), the rates of libido, erection and ejaculation problems did not differ significantly between dutasteride and finasteride (erectile dysfunction P=0.07) (Zhou et al., 2019). These trials were too small and short to show the two drugs are equally safe, and did not study effects after stopping.

The US label lists impotence, decreased libido, ejaculation disorders and breast enlargement or tenderness. It states that these sexual side effects may persist after treatment discontinuation, and that the role of dutasteride in this persistence is unknown. The label also lists depressed mood. In May 2026 the UK regulator (MHRA) added a mood warning for dutasteride and advised patients who develop depression or suicidal thoughts to contact a doctor as soon as possible. If you have thoughts of harming yourself, seek emergency help right away.

Concerns About Long-Term Safety:

Although dutasteride is effective in treating alopecia and other conditions, studies on its long-term effects are still limited. While there is strong evidence demonstrating its ability to reduce DHT, the lack of long-term safety data has led some doctors to be cautious. Finasteride, although not without risks, has been used for hair loss for longer and has more long-term data in young men. Since approval, some men have reported sexual problems, depression and suicidal thoughts, anxiety and cognitive complaints that continued after they stopped finasteride; the US label lists persisting sexual dysfunction, depression and suicidal ideation among post-marketing reports, which give no rate and cannot prove cause. "Post-finasteride syndrome" (PFS) is the name used for these symptoms. Researchers disagree about its causes, and there is no established test or treatment for it.

Similar concerns have been raised about dutasteride, which works in a similar way. How often lasting problems happen with either drug has not been well measured.

It Stays in the Body for Months

Dutasteride stays in the body for a long time. The US label gives a half-life of about 5 weeks, and blood levels can still be detected 4 to 6 months after the last dose. For this reason, men should not donate blood until at least 6 months after their last dose. In a label study, the drop in total sperm count had not reversed 24 weeks after stopping; the effect on fertility is not known. Dutasteride is not indicated for women. Women who are pregnant or may be pregnant should not handle the capsules, because the drug can be absorbed through the skin and may harm a male fetus.

Possible Link to Prostate Cancer and Effects on the Endocrine System

Another important consideration is the relationship between dutasteride and prostate cancer. In the 4-year REDUCE trial in men aged 50 to 75, fewer prostate cancers overall were found on biopsy with dutasteride, but Gleason score 8-10 (high-grade) cancer was found in 1.0% of men on dutasteride vs 0.5% on placebo (Andriole et al., 2010; Avodart label). The label states that 5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer. Dutasteride also lowers PSA, a prostate cancer blood test, by about 50%, so any doctor reading a PSA test needs to know you take it. Furthermore, dutasteride affects the endocrine system more intensely because it inhibits both isoforms of 5-alpha reductase (types I and II). This could have broader hormonal effects on the body, which may be of particular concern for younger men or individuals with a history of hormonal imbalances.

Preference for Proven and Well-Studied Treatments

Finasteride, despite having potential side effects, has been used for a longer time and has more clinical studies supporting its efficacy and safety in treating androgenic alopecia. Physicians often prefer to prescribe it first because finasteride 1 mg is approved for hair loss in more countries and has more long-term clinical data.

Conclusion

Dutasteride lowers DHT more than finasteride, but it is off-label for hair loss in most countries, stays in the body for months, and has less long-term data in young men. Its label states that sexual side effects may persist after stopping, it carries a precautionary UK warning about depression and suicidal thoughts, and it affects PSA testing and blood donation. For the full range of reported effects and their limits, see the FAQ "Dutasteride side effects: what the label and studies actually report". For these reasons, some physicians take a cautious approach when prescribing it. Patients considering dutasteride should discuss these factors with their doctor to determine whether it is the right treatment option for them.

Sources

Avodart (dutasteride) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=960797b3-09b1-4d6a-8ece-8b5d918e93e4

Zhou, Z., et al. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clinical Interventions in Aging, 14, 399-406. PMID 30863034. https://pubmed.ncbi.nlm.nih.gov/30863034/

Andriole, G. L., et al. (2010). Effect of dutasteride on the risk of prostate cancer. New England Journal of Medicine, 362(13), 1192-1202. PMID 20357281. https://pubmed.ncbi.nlm.nih.gov/20357281/

Medicines and Healthcare products Regulatory Agency. (2026, May 11). Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction